Moccasin-type Tinea Pedis Research Articles

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Naftifine hydrochloride gel 2% is effective as a topical therapy for moccasin-type tinea pedis

Naftifine hydrochloride gel 2% is effective as a topical therapy for moccasin-type tinea pedis

Erythematous skin macules with isolation of Trichophyton eboreum– infection or colonisation?

Dermatophytosis is among the most common skin diseases. They can be difficult to diagnose and are often mistaken with other diagnoses, for example tinea corporis can be mistaken as nummular eczema, impetigo, psoriasis or discoid lupus erythematosus. Atypical infectious agents are not infrequent. Recently, Trichophyton eboreum was characterised. The fungus was isolated from a moccasin-type tinea pedis in a HIV-positive patient. We report a case of eczema-like erythematous skin macules on the arms and the inguinal region of which, however, T. eboreum was isolated.

Trichophyton eboreum– Ein kürzlich beschriebener Dermatophyt

Background: The distribution of distinct species of dermatophytes is continuously changing and different species of dermatophytes can cause the same type of tinea.Therefore, it is necessary to always identify the pathogenic agents in dermatophytoses. Patients and Methods: An unusual fungus was isolated from moccasin type tinea pedis in a HIV-positive immunocompromised patient from the Ivory Coast and characterized by morphological, physiological and genetic methods. Results: The strain under study showed typical characteristics of dermatophytes but considering all its morphologic, physiologic and genetic features it unambiguously differed from all species described so far. Conclusion: The strain was, recently described as a new dermatophyte species (Trichophyton eboreum). Distribution and pathogenicity of this species are as yet unknown.

Trichophyton eboreum– A recently described dermatophyte

The distribution of distinct species of dermatophytes is continuously changing and different species of dermatophytes can cause the same type of tinea. Therefore, it is necessary to always identify the pathogenic agents in dermatophytoses. An unusual fungus was isolated from moccasin type tinea pedis in a HIV-positive immunocompromised patient from the Ivory Coast and characterized by morphological, physiological and genetic methods. The strain under study showed typical characteristics of dermatophytes but considering all its morphologic, physiologic and genetic features it unambiguously differed from all previously described species. The strain was recently described as a new dermatophyte species (Trichophyton eboreum). Distribution and pathogenicity of this species are as yet unknown.

Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis

Objective: To compare the clinical efficacy and tolerability of butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot).

Efficacy and Safety of Short-Term Itraconazole in Tinea pedis: A Double-Blind, Randomized, Placebo-Controlled Trial

Background: Treatment of plantar or moccasin-type tinea pedis with conventional oral antifungal agents produces poor response rates. Itraconazole is a synthetic, broad-spectrum, orally active antifungal agent with pronounced antimycotic activity. Objective: To confirm the efficacy and safety of short-term treatment with itraconazole for plantar or moccasin-type tinea pedis. Methods: The study was a double-blind, randomized, placebo-controlled, multicenter trial. Seventy-two patients with tinea pedis (plantar or moccasin-type) were treated with itraconazole (200 mg twice daily) or placebo for 1 week with an 8-week treatment-free follow-up period. Results: Thirty-six patients were randomized to each treatment group. The overall success rate (mycological cure and clinical response) at the end-point of follow-up was significantly higher in the itraconazole group than in the placebo group (53 vs. 3%; p <0.001). Mycological cure (56 vs. 8%; p <0.001) and clinical response rates (75 vs. 11%; p <0.001) were significantly higher after itraconazole treatment compared with placebo treatment. During treatment, adverse events were recorded in 7 patients in the itraconazole group and 2 patients in the placebo group. Adverse events were noted in 3 patients in the placebo group during follow-up. No serious adverse events were reported in either group. Conclusions: Short-term treatment with itraconazole was significantly more effective than placebo in tinea pedis. The safety and tolerability profile or itraconazole was comparable with placebo.

Topical terbinafine (Lamisilr`) for superficial mycoses: High cure rates in short treatment times

This review article compares the use of fungicidal terbinafine 1% cream in superficial mycoses with other more established and largely fungistatic agents. Topical azoles need to be applied two or three times daily for 4–6 weeks, whereas terbinafine has achieved cure rates in tinea pedis of 80–90% after only 1 or 2 weeks' treatment. Terbinafine twice daily for 1 week compared with clotrimazole twice daily for 4 weeks has produced mycological cure rates of 97.2% and 83.7%, respectively: a statistically significant result in favour of terbinafine. Terbinafine for 2 weeks produced a mycological cure in 69% of patients with moccasin-type tinea pedis. Treatment for 1–2 weeks with topical terbinafine has produced cure rates of 80–90% in tinea corporis and tinea cruris. Results have been similar in cutaneous candidosis and pityriasis versicolor.Two new terbinafine formulations are discussed: the 1% solution and 1% emulsion gel. One week's treatment with both formulations produces mycological cure rates in tinea pedis of 86% and 88% and in tinea corporis/cruris of 85% and 83%, respectively. Cure rates of 70–76% have been achieved in pityriasis versicolor after 1 week's treatment with the new formulations. The cream, solution and emulsion gel are all well tolerated. Though such newer drugs are relatively expensive, the much reduced duration of treatment and higher cure rates make them more cost-effective. (J Dermatol Treat (1998) 9(Suppl 1): S13–S16)

Multicentre double-blind study of efficacy and safety of terbinafine 1% cream compared with bifonazole 1% cream in patients with tinea pedis moccasin type

In a multicentre double-blind randomized parallel-group study, 78 patients with myologically proven moccasin-type tinea pedis were treated with terbinafine 1% cream or bifonazole 1% cream applied once daily for 2 weeks. The demographic data of both groups were comparable. Of 40 patients treated with terbinafine, the treatment was effective (i.e. mycological and clinical improvement) in 82.5% compared with 63.2% of 38 patients treated with bifonazole (P=0.05, test of proportion). Both creams were well tolerated. We conclude that topical terbinafine 1% cream is superior to bifonazole 1% cream in the treatment of moccasintype tinea pedis.

Efficacy of terbinafine 1% cream in the treatment of moccasin-type tinea pedis: Results of placebo-controlled multicenter trials

I. Dicken CH, Carrington SG, Winkelmann RK. Generalized granulomaannulare. Arch DermatolI969;99:556-63. 2. Mobacken H, Gisslen H, Johannisson G. Granuloma annulare:cortisone-glucose tolerancetest in a non-diabetic group. Acta Derm Venereal (Stockh) 1970;50:440-4. 3. Williamson DM, Dykes JRW. Carbohydrate metabolism in granuloma annulare. J InvestDermatol 1972;58:400-4. 4. BlohmeG, MobackenH, WaldenstromJ. Early insulinresponseto glucoseinjectedintravenously in patientswith 10calizedgranulomaannulare. ActaDerm Venereal(Stockh) 1974;54:259-63. 5. Haim S, Friedman-BirnbaumR, Shafir A, et al. Generalized granulomaannulare: relationshipto diabetes mellitus as revealed in 8 cases. Br J DermatoI1970;83:302-5. 6. Hammond R, DyessK, Castro A. Insulin productionand glucosetolerancein patients with granuloma annulare. Br J DermatoI1972;87:540-7. 7. Andersen BL, VerdichJ. Granuloma annulare and diabetes mellitus. Clin Exp Dermatol 1979;4:31-7. 8. Muhlemann MF, Williams DDR. Localized granuloma Briefcommunications 663

Treatment of chronic moccasin-type tinea pedis with terbinafine: A double-blind, placebo-controlled trial

Terbinafine is an orally and topically active fungicidal drug of the allylamine series. Its oral efficacy at 125 mg taken twice daily was evaluated in a randomized, double-blind, placebo-controlled study in moccasin-type tinea pedis. The study was conducted simultaneously in two centers and consisted of 41 evaluable cases (23 terbinafine, 18 placebo). Mycologie cure and near to complete clearing of signs and symptoms were obtained in 59% of the terbinafine-treated patients after 6 weeks of treatment and in 65% at 2 weeks after treatment. Corresponding efficacy for placebo-treated patients was zero at both evaluations. Side effects in both groups were minimal. We conclude that terbinafine is well tolerated and highly effective in moccasin-type tinea pedis.

Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis

The safety and effectiveness of oral terbinafine, 125 mg twice daily, and griseofulvin, 250 mg twice daily, in patients with moccasin-type tinea pedis were examined in a double-blind randomized trial. At the end of the 6-week treatment period, both a clinical and mycologie cure or a mycologie cure with minimal signs of infection was noted in 12 (75%) of the 16 terbin-afine-treated patients compared with only 3 (27%) of the 12 patients treated with griseofulvin. The overall response rate 2 weeks after the completion of treatment was 88% in the terbmafme-treated group and 45% in the griseofulvin-treated group. When contacted again 6 to 15 months after completion of the study, 94% of the terbinafine-treated patients reported sustained clearing of tinea pedis, and 88% of those with nail involvement at the time of treatment reported improvement. In contrast, tinea pedis remained cured in only 30% of the patients who had received griseofulvin, and onychomycosis improved in only 14%.

Terbinafine (Lamisil) versus griseofulvin in moccasin type tinea pedis

Terbinafine (Lamisil) is the first orally effective agent in a new family of antifungal drugs, the allylamines. As compared to the azoles, it has a unique site of action on sterol synthesis due to its inhibition of squalene epoxidase. The drug is highly effective against dermatophyte infections in vitro. In the study reported here, terbinafine is compared to griseofulvin in patients with moccasin-type tinea pedis. Terbinafine was given at 125 mg twice daily and griseofulvin was given at 250 mg (microsize) twice daily. Thirty-six patients were enrolled in a randomized double-blind study. Mycological culture microscopy was carried out and clinical signs and symptoms were assessed weekly for 6 weeks during therapy and at follow-up 2 weeks later. Twenty-eight of the 36 patients were evaluable for drug efficacy. Twelve out of sixteen (75%) of the terbinafine group were mycologically and clinically cured by the end of therapy (6 weeks) and 14 out of 16 (88%) were cured at the time of follow-up 2 weeks later. Two patients were mycologically cured, but moderate signs or symptoms were present at follow-up. In the griseofulvin-treated group 3 out of 12 (27%) were cured at the end of treatment and 5 out of 11 (45%) at follow-up evaluation. Follow-up after 6–15 months showed continued resolution in the terbinafine-treated patients, but relapse of infection in griseofulvin-treated patients. Terbinafine was found to be both safe and significantly more effective in this application than griseofulvin.

Sulconazole shows promise against chronic moccasin-type tinea pedis

Sulconazole shows promise against chronic moccasin-type tinea pedis

Sulconazole nitrate 1% cream in the treatment of chronic moccasin-type tinea pedis caused by Trichophyton rubrum

Sulconazole nitrate 1% cream applied twice daily was compared with its vehicle in the treatment of 229 patients with chronic moccasin-type tinea pedis confirmed by positive results of a potassium hydroxide preparation. At admission in this randomized, double-blind, parallel multicenter trial, 131 patients had positive dermatophyte cultures; Trichophyton rubrum was identified in 121 (92%). After 4 weeks of treatment, patients were examined and, if necessary, were treated for an additional 2 weeks. Sulconazole cream was significantly more effective than the vehicle in the treatment of chronic T. rubrum tinea pedis; 57% of patients were cured by sulconazole, compared with 13% cured with the vehicle. Relapse rates, assessed 2 weeks after the end of treatment, were significantly lower in patients treated with sulconazole than in those receiving vehicle (27% vs 71%). The 103 patients with moccasin-type tinea pedis whose cultures were not positive for T. rubrum achieved similar results.

Topical treatment for moccasin-type tinea pedis

Sixty patients were treated for tinea pedis with 2% topical ketoconazole cream either once or twice daily. All diagnoses were confirmed mycologically. They were randomly assigned in a double-blind study into three groups on the basis of their clinical lesions, that is, vesicular pedis, interdigital pedis, and hyperkeratotic "moccasin" pedis. Patients were treated for a period of 1 month and were evaluated weekly. A 4-week posttreatment evaluation permitted an assessment of recurrence or improvement. The follow-up visits showed 93% of the vesicular patients, 86% of the interdigital patients, and 83% of the moccasin patients had responded to topical ketoconazole therapy. The high percent of clinical efficacy seen in the first two groups corroborates treatment experiences held by most practicing dermatologists. Of practical interest, however, was the high number of responders among the moccasin-type of tinea pedis. Dermatologists rarely consider topical treatment useful for this clinical entity.